PCV90 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS SIMVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION BASED UPON THE JUPITER TRIAL
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72432-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)72432-9/fulltext
Title :
PCV90 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS SIMVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION BASED UPON THE JUPITER TRIAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72432-9&doi=10.1016/S1098-3015(11)72432-9
First page :
A358
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
593